Medivation Receives Average Recommendation of “Hold” from Analysts (NASDAQ:MDVN)
Medivation (NASDAQ:MDVN) has been given a consensus recommendation of “Hold” by the twenty-one brokerages that are currently covering the stock, Analyst Ratings.Net reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $97.00.
In other Medivation news, Insider Lynn Seely sold 20,000 shares of the stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $83.62, for a total transaction of $1,672,400.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
A number of research firms have recently commented on MDVN. Analysts at Zacks reiterated a “neutral” rating on shares of Medivation in a research note on Monday. They now have a $89.00 price target on the stock. Separately, analysts at Jefferies Group reiterated a “positive” rating on shares of Medivation in a research note on Monday, August 18th. Finally, analysts at Aegis raised their price target on shares of Medivation from $125.00 to $130.00 in a research note on Friday, August 8th.
Medivation (NASDAQ:MDVN) opened at 88.70 on Tuesday. Medivation has a one year low of $48.15 and a one year high of $88.85. The stock has a 50-day moving average of $78.3 and a 200-day moving average of $72.13. The company has a market cap of $6.811 billion and a P/E ratio of 285.21.
Medivation (NASDAQ:MDVN) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.60 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.24 by $0.36. The company had revenue of $148.09 million for the quarter, compared to the consensus estimate of $126.46 million. During the same quarter in the prior year, the company posted ($0.07) earnings per share. The company’s quarterly revenue was up 111.1% on a year-over-year basis. On average, analysts predict that Medivation will post $2.43 earnings per share for the current fiscal year.
Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.
Receive News & Ratings for Medivation Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medivation Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.